抽动秽语综合征的当代评价与药物治疗

Lawrence Scahill, Gerald Erenberg, Cheston M. Berlin Jr, Cathy Budman, Barbara J. Coffey, Joseph Jankovic, Louise Kiessling, Robert A. King, Roger Kurlan, Anthony Lang, Jonathan Mink, Tanya Murphy, Samual Zinner, John Walkup
{"title":"抽动秽语综合征的当代评价与药物治疗","authors":"Lawrence Scahill,&nbsp;Gerald Erenberg,&nbsp;Cheston M. Berlin Jr,&nbsp;Cathy Budman,&nbsp;Barbara J. Coffey,&nbsp;Joseph Jankovic,&nbsp;Louise Kiessling,&nbsp;Robert A. King,&nbsp;Roger Kurlan,&nbsp;Anthony Lang,&nbsp;Jonathan Mink,&nbsp;Tanya Murphy,&nbsp;Samual Zinner,&nbsp;John Walkup","doi":"10.1016/j.nurx.2006.01.009","DOIUrl":null,"url":null,"abstract":"<div><h3>Summary</h3><p>To develop a guide to clinical assessment and pharmacotherapy for children and adults with Tourette syndrome (TS), we reviewed published literature over the past 25 years to identify original articles and reviews on the assessment and pharmacological treatment of Tourette syndrome, attention–deficit/hyperactivity disorder (ADHD) and obsessive–compulsive disorder (OCD). The literature search also included a survey of reviews published in book chapters. The assessment section was compiled from several reviews. Pharmacological treatments were classified into those with strong empirical support (as evidenced by two positive placebo-controlled studies for tics, OCD, or ADHD in TS samples); modest empirical support (one positive placebo-controlled study), or minimal support (open-label data only). We conclude that accurate diagnosis, including identification of comorbid conditions, is an essential step toward appropriate treatment for patients with TS. In many patients with TS, symptom management requires pharmacotherapy for tics or coexisting conditions. The evidence supporting efficacy and safety for medications used in patients with TS varies. But this evidence offers the best guide to clinical practice.</p></div>","PeriodicalId":87195,"journal":{"name":"NeuroRx : the journal of the American Society for Experimental NeuroTherapeutics","volume":"3 2","pages":"Pages 192-206"},"PeriodicalIF":0.0000,"publicationDate":"2006-04-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.1016/j.nurx.2006.01.009","citationCount":"252","resultStr":"{\"title\":\"Contemporary Assessment and Pharmacotherapy of Tourette Syndrome\",\"authors\":\"Lawrence Scahill,&nbsp;Gerald Erenberg,&nbsp;Cheston M. Berlin Jr,&nbsp;Cathy Budman,&nbsp;Barbara J. Coffey,&nbsp;Joseph Jankovic,&nbsp;Louise Kiessling,&nbsp;Robert A. King,&nbsp;Roger Kurlan,&nbsp;Anthony Lang,&nbsp;Jonathan Mink,&nbsp;Tanya Murphy,&nbsp;Samual Zinner,&nbsp;John Walkup\",\"doi\":\"10.1016/j.nurx.2006.01.009\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<div><h3>Summary</h3><p>To develop a guide to clinical assessment and pharmacotherapy for children and adults with Tourette syndrome (TS), we reviewed published literature over the past 25 years to identify original articles and reviews on the assessment and pharmacological treatment of Tourette syndrome, attention–deficit/hyperactivity disorder (ADHD) and obsessive–compulsive disorder (OCD). The literature search also included a survey of reviews published in book chapters. The assessment section was compiled from several reviews. Pharmacological treatments were classified into those with strong empirical support (as evidenced by two positive placebo-controlled studies for tics, OCD, or ADHD in TS samples); modest empirical support (one positive placebo-controlled study), or minimal support (open-label data only). We conclude that accurate diagnosis, including identification of comorbid conditions, is an essential step toward appropriate treatment for patients with TS. In many patients with TS, symptom management requires pharmacotherapy for tics or coexisting conditions. The evidence supporting efficacy and safety for medications used in patients with TS varies. But this evidence offers the best guide to clinical practice.</p></div>\",\"PeriodicalId\":87195,\"journal\":{\"name\":\"NeuroRx : the journal of the American Society for Experimental NeuroTherapeutics\",\"volume\":\"3 2\",\"pages\":\"Pages 192-206\"},\"PeriodicalIF\":0.0000,\"publicationDate\":\"2006-04-01\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"https://sci-hub-pdf.com/10.1016/j.nurx.2006.01.009\",\"citationCount\":\"252\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"NeuroRx : the journal of the American Society for Experimental NeuroTherapeutics\",\"FirstCategoryId\":\"1085\",\"ListUrlMain\":\"https://www.sciencedirect.com/science/article/pii/S1545534306000289\",\"RegionNum\":0,\"RegionCategory\":null,\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"\",\"JCRName\":\"\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"NeuroRx : the journal of the American Society for Experimental NeuroTherapeutics","FirstCategoryId":"1085","ListUrlMain":"https://www.sciencedirect.com/science/article/pii/S1545534306000289","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}
引用次数: 252

摘要

摘要:为了制定图雷特综合征(TS)儿童和成人的临床评估和药物治疗指南,我们回顾了过去25年发表的文献,以确定图雷特综合征、注意缺陷/多动障碍(ADHD)和强迫症(OCD)的评估和药物治疗的原始文章和综述。文献检索还包括对书籍章节中发表的评论的调查。评估部分是根据几项审查汇编的。药物治疗被分类为具有强烈经验支持的治疗(如在TS样本中对抽搐、强迫症或多动症进行的两项阳性安慰剂对照研究);适度的经验支持(一项积极的安慰剂对照研究),或最小的支持(仅开放标签数据)。我们的结论是,准确的诊断,包括识别合并症,是对TS患者进行适当治疗的重要一步。在许多TS患者中,症状管理需要药物治疗抽搐或共存疾病。支持对TS患者使用药物的有效性和安全性的证据各不相同。但这一证据为临床实践提供了最好的指导。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
Contemporary Assessment and Pharmacotherapy of Tourette Syndrome

Summary

To develop a guide to clinical assessment and pharmacotherapy for children and adults with Tourette syndrome (TS), we reviewed published literature over the past 25 years to identify original articles and reviews on the assessment and pharmacological treatment of Tourette syndrome, attention–deficit/hyperactivity disorder (ADHD) and obsessive–compulsive disorder (OCD). The literature search also included a survey of reviews published in book chapters. The assessment section was compiled from several reviews. Pharmacological treatments were classified into those with strong empirical support (as evidenced by two positive placebo-controlled studies for tics, OCD, or ADHD in TS samples); modest empirical support (one positive placebo-controlled study), or minimal support (open-label data only). We conclude that accurate diagnosis, including identification of comorbid conditions, is an essential step toward appropriate treatment for patients with TS. In many patients with TS, symptom management requires pharmacotherapy for tics or coexisting conditions. The evidence supporting efficacy and safety for medications used in patients with TS varies. But this evidence offers the best guide to clinical practice.

求助全文
通过发布文献求助,成功后即可免费获取论文全文。 去求助
来源期刊
自引率
0.00%
发文量
0
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:604180095
Book学术官方微信